Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 196712, 7 pages
http://dx.doi.org/10.1155/2014/196712
Research Article

In Vitro Inhibition of Hepatitis C Virus by Antisense Oligonucleotides in PBMC Compared to Hepatoma Cells

1Microbial Biotechnology Department, National Research Center, Cairo 12311, Egypt
2Reproductive Health and Family Planning Department, National Research Center, Cairo, Egypt
3INRS-Institut Armand Frappier, Laval, QC, Canada H7V 1B7
4Chemistry Department, Faculty of Science, Cairo University, Cairo 12613, Egypt

Received 17 February 2014; Revised 7 April 2014; Accepted 10 April 2014; Published 1 June 2014

Academic Editor: Ramesh Prabhu

Copyright © 2014 Samar Samir Youssef et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. M. Lauer and B. D. Walker, “Hepatitis C virus infection,” The New England Journal of Medicine, vol. 345, no. 1, pp. 41–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Hoofnagle, “Course and outcome of hepatitis C,” Hepatology, vol. 36, no. 5, supplement 1, pp. S21–S29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Alter, “Epidemiology of hepatitis C virus infection,” World Journal of Gastroenterology, vol. 13, no. 17, pp. 2436–2441, 2007. View at Google Scholar · View at Scopus
  4. “Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium,” Journal of Viral Hepatitis, vol. 6, no. 1, pp. 35–47, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Ducoulombier, A. Roque-Afonso, G. Di Liberto et al., “Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes,” Hepatology, vol. 39, no. 3, pp. 817–825, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. T. Blackard, N. Kemmer, and K. E. Sherman, “Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences,” Hepatology, vol. 44, no. 1, pp. 15–22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Pal, D. G. Sullivan, S. Kim et al., “Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism,” Gastroenterology, vol. 130, no. 4, pp. 1107–1116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. T. N. Q. Pham, S. A. MacParland, P. M. Mulrooney, H. Cooksley, N. V. Naoumov, and T. I. Michalak, “Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C,” Journal of Virology, vol. 78, no. 11, pp. 5867–5874, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Radkowski, J. F. Gallegos-Orozco, J. Jablonska et al., “Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C,” Hepatology, vol. 41, no. 1, pp. 106–114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Z. Xu, Y. Xie, and Z. Q. Li, “Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C,” Hepatobiliary and Pancreatic Diseases International, vol. 4, no. 4, pp. 550–553, 2005. View at Google Scholar · View at Scopus
  11. P. Simmonds, “Genetic diversity and evolution of hepatitis C virus—15 years on,” Journal of General Virology, vol. 85, no. 11, pp. 3173–3188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Sievert, I. Altraif, H. A. Razavi et al., “A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt,” Liver International, vol. 31, supplement 2, pp. 61–80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Abdel-Aziz, M. Habib, M. K. Mohamed et al., “Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence,” Hepatology, vol. 32, no. 1, pp. 111–115, 2000. View at Google Scholar · View at Scopus
  14. S. Franco, C. Tural, B. Clotet, and M. A. Martínez, “Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1,” Virus Research, vol. 123, no. 2, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. G. Ghany, D. R. Nelson, D. B. Strader, D. L. Thomas, and L. B. Seeff, “An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases,” Hepatology, vol. 54, no. 4, pp. 1433–1444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Kamal and I. A. Nasser, “Hepatitis C genotype 4: what we know and what we don't yet know,” Hepatology, vol. 47, no. 4, pp. 1371–1383, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. González-Carmona, A. Vogt, T. Heinicke et al., “Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivo,” Journal of Hepatology, vol. 55, no. 1, pp. 19–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Aman, S. Mousa, G. Shiha, and S. A. Mousa, “Current status and future directions in the management of chronic hepatitis C,” Virology Journal, vol. 9, article 57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. L. Shiffman and R. Esteban, “Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?” Liver International, vol. 32, no. 1, pp. 54–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Bukh, R. H. Purcell, and R. H. Miller, “Sequence analysis of the 5′ noncoding region of hepatitis C virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 11, pp. 4942–4946, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. J. G. McHutchison, K. Patel, P. Pockros et al., “A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients,” Journal of Hepatology, vol. 44, no. 1, pp. 88–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. El-Awady, N. G. B. El-Din, W. T. El-Garf et al., “Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells,” Cancer Cell International, vol. 6, article 18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Alt, R. Renz, P. H. Hofschneider, G. Paumgartner, and W. H. Caselmann, “Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides,” Hepatology, vol. 22, no. 3, pp. 707–717, 1995. View at Google Scholar · View at Scopus
  24. M. Gonzalez-Carmona, S. Schüssler, M. Serwe et al., “Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells,” Journal of Hepatology, vol. 44, no. 6, pp. 1017–1025, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Guerniou, R. Gillet, F. Berrée, B. Carboni, and B. Felden, “Targeted inhibition of the hepatitis C internal ribosomal entry site genomic RNA with oligonucleotide conjugates,” Nucleic Acids Research, vol. 35, no. 20, pp. 6778–6787, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. González-Carmona, M. Quasdorff, A. Vogt et al., “Inhibition of hepatitis C virus RNA translation by antisense bile acid conjugated phosphorothioate modified oligodeoxynucleotides (ODN),” Antiviral Research, vol. 97, no. 1, pp. 49–59, 2013. View at Publisher · View at Google Scholar
  27. T. Ohno, M. Mizokami, R. Wu et al., “New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a,” Journal of Clinical Microbiology, vol. 35, no. 1, pp. 201–207, 1997. View at Google Scholar · View at Scopus
  28. M. K. El-Awady, H. M. Azzazy, A. M. Fahmy et al., “Positional effect of mutations in 5′UTR of hepatitis C virus 4a on patients' response to therapy,” World Journal of Gastroenterology, vol. 15, no. 12, pp. 1480–1486, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. K. El-Awady, S. S. Youssef, M. H. Omran, A. A. Tabll, W. T. El-Garf, and A. M. Salem, “Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection,” BMC Infectious Diseases, vol. 6, article 91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Hanecak, V. Brown-Driver, M. C. Fox et al., “Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes,” Journal of Virology, vol. 70, no. 8, pp. 5203–5212, 1996. View at Google Scholar · View at Scopus
  31. M. Seki and Y. Honda, “Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay,” Journal of Biochemistry, vol. 118, no. 6, pp. 1199–1204, 1995. View at Google Scholar · View at Scopus
  32. O. Vidalin, M. E. Major, B. Rayner, J. L. Imbach, C. Trépo, and G. Inchauspé, “In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 10, pp. 2337–2344, 1996. View at Google Scholar · View at Scopus
  33. T. Wakita and J. R. Wands, “Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence,” Journal of Biological Chemistry, vol. 269, no. 19, pp. 14205–14210, 1994. View at Google Scholar · View at Scopus
  34. H. Zhang, R. Hanecak, V. Brown-Driver et al., “Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 2, pp. 347–353, 1999. View at Google Scholar · View at Scopus
  35. H. Dahari, A. Feliu, M. Garcia-Retortillo, X. Forns, and A. U. Neumann, “Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation,” Journal of Hepatology, vol. 42, no. 4, pp. 491–498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Pugnale, E. Herrmann, A. U. Neumann et al., “Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-α2a/ribavirin therapy,” Journal of Hepatology, vol. 48, no. 6, pp. 932–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Z. Gong, L. Y. Lai, Y. F. Jiang, Y. He, and X. S. Su, “HCV replication in PBMC and its influence on interferon therapy,” World Journal of Gastroenterology, vol. 9, no. 2, pp. 291–294, 2003. View at Google Scholar · View at Scopus
  38. S. L. Fishman and A. D. Branch, “The quasispecies nature and biological implications of the hepatitis C virus,” Infection, Genetics and Evolution, vol. 9, no. 6, pp. 1158–1167, 2009. View at Publisher · View at Google Scholar